Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 17 | 2025 | 1765 | 0.900 |
Why?
|
| Genome, Human | 6 | 2023 | 824 | 0.890 |
Why?
|
| Iceland | 16 | 2024 | 20 | 0.840 |
Why?
|
| Genotyping Techniques | 2 | 2019 | 71 | 0.730 |
Why?
|
| Genomic Structural Variation | 1 | 2019 | 9 | 0.630 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2025 | 2494 | 0.540 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2024 | 2474 | 0.540 |
Why?
|
| Software | 2 | 2019 | 698 | 0.490 |
Why?
|
| Loss of Function Mutation | 4 | 2024 | 50 | 0.460 |
Why?
|
| Blood Proteins | 2 | 2023 | 151 | 0.370 |
Why?
|
| Genetic Variation | 5 | 2022 | 1423 | 0.360 |
Why?
|
| United Kingdom | 7 | 2024 | 192 | 0.320 |
Why?
|
| Phenotype | 5 | 2023 | 2579 | 0.310 |
Why?
|
| Databases, Genetic | 2 | 2022 | 284 | 0.310 |
Why?
|
| Homozygote | 3 | 2024 | 208 | 0.300 |
Why?
|
| Genomics | 2 | 2023 | 857 | 0.260 |
Why?
|
| Proteome | 3 | 2023 | 156 | 0.260 |
Why?
|
| Proteomics | 3 | 2023 | 268 | 0.260 |
Why?
|
| Mutation, Missense | 2 | 2025 | 302 | 0.250 |
Why?
|
| Asthma | 2 | 2024 | 1051 | 0.250 |
Why?
|
| Germ-Line Mutation | 3 | 2024 | 382 | 0.240 |
Why?
|
| Genotype | 4 | 2023 | 1882 | 0.240 |
Why?
|
| Quantitative Trait Loci | 4 | 2023 | 632 | 0.230 |
Why?
|
| Biological Specimen Banks | 2 | 2023 | 72 | 0.230 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 346 | 0.230 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 334 | 0.230 |
Why?
|
| STAT6 Transcription Factor | 1 | 2024 | 29 | 0.220 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2024 | 13 | 0.220 |
Why?
|
| Thyroiditis, Autoimmune | 2 | 2024 | 17 | 0.220 |
Why?
|
| Whole Genome Sequencing | 2 | 2022 | 109 | 0.220 |
Why?
|
| Codon, Initiator | 1 | 2024 | 18 | 0.220 |
Why?
|
| Humans | 33 | 2025 | 96112 | 0.210 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2024 | 23 | 0.210 |
Why?
|
| Receptors, Notch | 1 | 2024 | 136 | 0.210 |
Why?
|
| Migraine with Aura | 1 | 2023 | 4 | 0.210 |
Why?
|
| Wnt Signaling Pathway | 1 | 2024 | 103 | 0.210 |
Why?
|
| Body Mass Index | 2 | 2025 | 815 | 0.210 |
Why?
|
| Urticaria | 1 | 2023 | 15 | 0.200 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2025 | 307 | 0.200 |
Why?
|
| Migraine Disorders | 1 | 2023 | 43 | 0.200 |
Why?
|
| Case-Control Studies | 6 | 2024 | 1958 | 0.190 |
Why?
|
| Disease Susceptibility | 1 | 2023 | 220 | 0.190 |
Why?
|
| RNA Splice Sites | 2 | 2020 | 58 | 0.190 |
Why?
|
| Antigens, CD | 1 | 2024 | 482 | 0.190 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 481 | 0.190 |
Why?
|
| Viral Vaccines | 1 | 2022 | 48 | 0.190 |
Why?
|
| Computer Graphics | 2 | 2019 | 102 | 0.190 |
Why?
|
| Alleles | 5 | 2025 | 1157 | 0.180 |
Why?
|
| Genetic Loci | 2 | 2020 | 260 | 0.180 |
Why?
|
| Platelet Count | 1 | 2021 | 97 | 0.180 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2021 | 6 | 0.170 |
Why?
|
| Pedigree | 2 | 2020 | 982 | 0.170 |
Why?
|
| Penetrance | 1 | 2021 | 48 | 0.170 |
Why?
|
| Disease | 1 | 2021 | 93 | 0.170 |
Why?
|
| Epidemics | 1 | 2021 | 41 | 0.170 |
Why?
|
| Benchmarking | 1 | 2021 | 82 | 0.170 |
Why?
|
| Receptors, LDL | 1 | 2020 | 54 | 0.170 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2021 | 63 | 0.170 |
Why?
|
| Hearing Loss | 1 | 2021 | 65 | 0.170 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 57 | 0.170 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2022 | 187 | 0.160 |
Why?
|
| Wnt4 Protein | 1 | 2020 | 4 | 0.160 |
Why?
|
| Codon, Nonsense | 1 | 2020 | 47 | 0.160 |
Why?
|
| Epidemiological Monitoring | 1 | 2020 | 43 | 0.160 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 74 | 0.160 |
Why?
|
| Gene Frequency | 4 | 2024 | 703 | 0.160 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2020 | 132 | 0.150 |
Why?
|
| Uterine Prolapse | 1 | 2020 | 82 | 0.150 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2020 | 130 | 0.150 |
Why?
|
| Peripherins | 1 | 2019 | 4 | 0.150 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 187 | 0.150 |
Why?
|
| Sural Nerve | 1 | 2019 | 18 | 0.150 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 246 | 0.150 |
Why?
|
| Workflow | 1 | 2019 | 80 | 0.150 |
Why?
|
| Epilepsy | 1 | 2023 | 451 | 0.150 |
Why?
|
| Neural Conduction | 1 | 2019 | 72 | 0.150 |
Why?
|
| Ligands | 1 | 2020 | 478 | 0.150 |
Why?
|
| Polyneuropathies | 1 | 2019 | 26 | 0.150 |
Why?
|
| Genomic Imprinting | 1 | 2018 | 32 | 0.150 |
Why?
|
| Inheritance Patterns | 1 | 2018 | 52 | 0.140 |
Why?
|
| Female | 16 | 2025 | 50045 | 0.140 |
Why?
|
| Obesity | 1 | 2025 | 1034 | 0.140 |
Why?
|
| Biomarkers | 2 | 2021 | 1932 | 0.140 |
Why?
|
| Proteins | 1 | 2023 | 816 | 0.140 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 319 | 0.130 |
Why?
|
| Male | 14 | 2025 | 45871 | 0.130 |
Why?
|
| Base Sequence | 2 | 2017 | 2344 | 0.130 |
Why?
|
| Genetics, Population | 1 | 2019 | 437 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 793 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 625 | 0.120 |
Why?
|
| Parents | 1 | 2018 | 307 | 0.120 |
Why?
|
| Mutation | 3 | 2023 | 4374 | 0.110 |
Why?
|
| Middle Aged | 9 | 2024 | 28371 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 910 | 0.100 |
Why?
|
| Haplotypes | 3 | 2022 | 650 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2018 | 703 | 0.100 |
Why?
|
| Ireland | 2 | 2023 | 12 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2883 | 0.100 |
Why?
|
| Africa | 2 | 2023 | 107 | 0.100 |
Why?
|
| Transcriptome | 1 | 2018 | 769 | 0.100 |
Why?
|
| Adult | 8 | 2024 | 28725 | 0.090 |
Why?
|
| Autoimmune Diseases | 2 | 2024 | 257 | 0.080 |
Why?
|
| HLA Antigens | 2 | 2024 | 231 | 0.080 |
Why?
|
| Vaccination | 2 | 2022 | 311 | 0.080 |
Why?
|
| RNA Splicing | 2 | 2023 | 159 | 0.080 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 348 | 0.080 |
Why?
|
| Aged | 6 | 2023 | 20972 | 0.070 |
Why?
|
| Neoplasms | 1 | 2024 | 3248 | 0.070 |
Why?
|
| Algorithms | 1 | 2017 | 2015 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1276 | 0.070 |
Why?
|
| Betacoronavirus | 2 | 2020 | 284 | 0.060 |
Why?
|
| Young Adult | 3 | 2024 | 7025 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2090 | 0.060 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2025 | 5 | 0.060 |
Why?
|
| Finland | 1 | 2025 | 31 | 0.060 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2025 | 31 | 0.060 |
Why?
|
| Adolescent | 3 | 2024 | 9895 | 0.060 |
Why?
|
| Norway | 1 | 2024 | 10 | 0.060 |
Why?
|
| Denmark | 1 | 2024 | 19 | 0.060 |
Why?
|
| Vitiligo | 1 | 2024 | 19 | 0.050 |
Why?
|
| 5' Untranslated Regions | 1 | 2024 | 54 | 0.050 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2024 | 99 | 0.050 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2024 | 129 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2024 | 109 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2024 | 68 | 0.050 |
Why?
|
| Wnt Proteins | 1 | 2024 | 131 | 0.050 |
Why?
|
| Immunoglobulin E | 1 | 2024 | 152 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2024 | 136 | 0.050 |
Why?
|
| Pandemics | 2 | 2020 | 880 | 0.050 |
Why?
|
| Menopause | 1 | 2024 | 90 | 0.050 |
Why?
|
| Plasma | 1 | 2023 | 51 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2022 | 3110 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2023 | 82 | 0.050 |
Why?
|
| Genes, Recessive | 1 | 2023 | 87 | 0.050 |
Why?
|
| Mast Cells | 1 | 2023 | 97 | 0.050 |
Why?
|
| Autophagy | 1 | 2024 | 177 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2023 | 183 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 60 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2022 | 33 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2024 | 453 | 0.050 |
Why?
|
| Asia | 1 | 2022 | 105 | 0.050 |
Why?
|
| STAT Transcription Factors | 1 | 2022 | 18 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2022 | 9 | 0.050 |
Why?
|
| Janus Kinases | 1 | 2022 | 24 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2022 | 151 | 0.050 |
Why?
|
| Conserved Sequence | 1 | 2022 | 215 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 2022 | 215 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2024 | 488 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2023 | 327 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2021 | 58 | 0.040 |
Why?
|
| Tissue Banks | 1 | 2021 | 16 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2022 | 157 | 0.040 |
Why?
|
| Gain of Function Mutation | 1 | 2020 | 15 | 0.040 |
Why?
|
| Child | 2 | 2024 | 7625 | 0.040 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 23 | 0.040 |
Why?
|
| Exons | 1 | 2022 | 454 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 276 | 0.040 |
Why?
|
| Quarantine | 1 | 2020 | 9 | 0.040 |
Why?
|
| 3' Untranslated Regions | 1 | 2020 | 100 | 0.040 |
Why?
|
| Genes | 1 | 2021 | 308 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2021 | 157 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2020 | 126 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 311 | 0.040 |
Why?
|
| Contact Tracing | 1 | 2020 | 29 | 0.040 |
Why?
|
| Risk Factors | 2 | 2021 | 5961 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2020 | 296 | 0.040 |
Why?
|
| Heterozygote | 1 | 2020 | 382 | 0.040 |
Why?
|
| Travel | 1 | 2020 | 72 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 7230 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2020 | 358 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2020 | 446 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2020 | 220 | 0.040 |
Why?
|
| Introns | 1 | 2020 | 304 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2022 | 503 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 713 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 595 | 0.040 |
Why?
|
| Prader-Willi Syndrome | 1 | 2018 | 8 | 0.040 |
Why?
|
| Angelman Syndrome | 1 | 2018 | 7 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2020 | 489 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2018 | 66 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 930 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 344 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 667 | 0.030 |
Why?
|
| Axons | 1 | 2019 | 189 | 0.030 |
Why?
|
| CpG Islands | 1 | 2018 | 169 | 0.030 |
Why?
|
| Liver | 1 | 2022 | 1238 | 0.030 |
Why?
|
| Pan paniscus | 1 | 2017 | 10 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 565 | 0.030 |
Why?
|
| Animals | 3 | 2023 | 28919 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2017 | 360 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 1981 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 1963 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1011 | 0.030 |
Why?
|
| Aging | 1 | 2021 | 766 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1010 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2020 | 592 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2017 | 481 | 0.030 |
Why?
|
| Mass Screening | 1 | 2020 | 710 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1349 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 2537 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 841 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 540 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 429 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 3363 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2020 | 3974 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 2480 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3927 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2022 | 3581 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 12541 | 0.020 |
Why?
|